A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients
Journal Title: Annals of Hepatology - Year 2012, Vol 11, Issue 2
Abstract
Purpose. Chronic hepatitis C virus (HCV) is a major problem affecting up to 170 million people worldwide. Two protease inhibitors have recently been approved that will revolutionize treatment. Our objective was to summarize and evaluate the literature pertaining to the pharmacokinetics of boceprevir and telaprevir, in order to provide clinicians with insight into the management of actual and potential drug interactions.Summary. A standardized search using MEDLINE (1948-November 2011), EMBASE (1980-November 2011), IPA (1970-November 2011), Google, and Google Scholar that combined the search terms boceprevir, telaprevir, pharmacokinetics, drug interaction, and drug metabolism was performed. Manual reference searches of chosen articles were completed. Monographs and articles, conference proceedings, and abstracts were evaluated. Boceprevir and telaprevir are both substrates and inhibitors of cytochrome P450 3A4 and telaprevir is a substrate of p-glycoprotein. Levels of boceprevir are decreased in patients taking efavirenz but effects with other antiretrovirals are minimal or unknown. Coadministration with efavirenz may compromisetelaprevir levels and should be avoided. Telaprevir may increase levels of cyclosporine, tacrolimus, atorvastatin, and amlodipine, which may expose patients to increased adverse effects. Conclusions. Significant drug-drug interactions occur with both boceprevir and telaprevir. Until studies are reported and experience is gained with these agents, clinicians will need to be careful when administering in high-risk populations and those receiving chronic therapy with interacting agents. Studies are urgently needed in HIV patients taking antiretrovirals and patients taking chronic immunosuppresion as these populations are at increased risk of experiencing clinically significant interactions.
Authors and Affiliations
Kyle Wilby, Erica Greanya, Jo-Ann Ford, Eric Yoshida, Nilufar Partovi
Keywords
Related Articles
- EP ID EP78120
- DOI -
- Views 121
- Downloads 0
Budd Chiari syndrome without evidence for thrombosis. Is it still a Budd Chiari ?
DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma
Introduction. Hypermethylation of relevant genes may affect the prognosis of patients with cancer. Thepurpose of this study was to analyze whether methylation of the promoter regions of cell cycle regulatorsas well as el...
Determination of ammonia concentrations in cirrhosis patients-still confusing after all these years?
By the end of the nineteenth century, ammonia had been identified as the main factor responsible for hepatic encephalopathy syndrome. Ammonia is one of the principal products of hepatic metabolism and high concentrations...
Aspartate aminotransferase-to-platelet ratio index (APRI) for the non-invasive prediction of esophageal varices
Background & Aims. Variceal bleeding is a dramatic and common complication of cirrhosis, and, therefore, endoscopy is recommended for the screening of EV (esophageal varices) in every cirrhotic. This study ev...
Redox state and methods to evaluate oxidative stress in liver damage: From bench to bedside
Oxidative stress is importantly involved in the pathophysiology of various liver diseases. The redox state participates on the courseof the inflammatory, metabolic and proliferative liver diseases. The main sources of t...